Recent advances of engineered oncolytic viruses-based combination therapy for liver cancer

• DOI: 10.1186/s12967-023-04817-w
• Publication Date: 2024-01-02T13:02:26Z
• Authors: Junhe Zhang; Yunxi Xiao; Jie Zhang; Yun Yang; Liao Zhang; Fan Liang
• Keywords: Oncolytic Virotherapy; 0303 health sciences; Oncolytic virus; Liver Neoplasms; R; Review; Genetic Therapy; Targeted therapy; Oncolytic Viruses; 03 medical and health sciences; Gene therapy; Neoplasms; Medicine; Humans; Immunotherapy; Liver cancer

AbstractLiver cancer is a major malignant tumor, which seriously threatens human health and increases the economic burden on patients. At present, gene therapy has been comprehensively studied as an excellent therapeutic measure in liver cancer treatment. Oncolytic virus (OV) is a kind of virus that can specifically infect and kill tumor cells. After being modified by genetic engineering, the specificity of OV infection to tumor cells is increased, and its influence on normal cells is reduced. To date, OV has shown its effectiveness and safety in experimental and clinical studies on a variety of tumors. Thus, this review primarily introduces the current status of different genetically engineered OVs used in gene therapy for liver cancer, focuses on the application of OVs and different target genes for current liver cancer therapy, and identifies the problems encountered in OVs-based combination therapy and the corresponding solutions, which will provide new insights into the treatment of liver cancer.